Tuvirumab  (Synonyms: 妥韦单抗; anti-hepatitis B; OST 577; SDZ-OST 577)

Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research^[1][2].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Human

Tuvirumab (OST 577; SDZ-OST 577; 5 mg/kg; 静脉给药; 单次剂量) 预处理后，静脉注射野生型 HBV，即 MS-2 毒株，可以靶向黑猩猩延迟的 HBV 表面抗原决定簇，但不能预防实验性感染的 HBV 和肝炎^[1]。
Tuvirumab (5 mg/kg; 静脉注射) 在黑猩猩中的半衰期为 16.7 天^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

138660-97-6

妥韦单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. N Ogata, et al. Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3014-8.  [Content Brief]

  [2]. R A Heijtink, et al. Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes. J Med Virol. 2001 Aug;64(4):427-34.  [Content Brief]